The shift from broad immunosuppression (via TNF-α inhibitors) to more specific immune modulation with ustekinumab may help avoid further exacerbations of paradoxical psoriasis while effectively controlling the underlying condition (3). The gene discussed is TNF; the disease is psoriasis.